CASE PRESENTATION
A 75-year-old woman presented to the emergency department after experiencing an unwitnessed fall at home. She had been experiencing symptoms consistent with vertigo for a few days before presentation. Her medical history was significant for hypertension, type 2 diabetes mellitus, psoriasis, dyslipidemia, a seizure disorder and right knee arthroplasty. Collateral history revealed that she had been assessed one week before for a planned total left knee arthroplasty, which had subsequently been postponed after the patient had been found to have a truncal rash that had been present for two weeks.
Her physical examination was significant for a petechial maculopapular rash on her chest, arms and legs, as well as a positive DixHallpike test. Vitals signs were within normal parameters and she was afebrile. Initial laboratory investigations (electrolytes, urea, creatinine, glucose) were unremarkable. She had a hemoglobin level of 138 g/L, white blood cell count of 9.0×10 9 cells/L and a platelet count of 176×10 9 /L. While in the emergency department, a peripheral intravenous (IV) catheter was placed at the dorsum of her left hand for administration of fluids.
The patient was admitted for further assessment and evaluation. Twelve hours later, she became febrile, but was otherwise asymptomatic. Two blood samples were drawn from separate venipuncture sites and sent for culture. Both sets of blood cultures were positive for Gram-positive cocci in clusters. She was then administered empirical IV vancomycin (1 g every 12 h).
Staphylococcus pettenkoferi was isolated in both blood cultures using a 3 h short-incubation matrix-assisted laser desorption/ionization time-of-flight (MALDI-ToF) identification protocol. It was approximately 36 h from the time of blood culture draws until preliminary results demonstrated coagulase-negative staphylococci, and 51 h for the final culture result of S pettenkoferi. The positive blood cultures were subcultured onto a Columbia blood-agar plate (Oxoid, Thermo Fisher Scientific Inc, USA) and incubated at 35°C in 5% CO 2 for 3 h. Identification of the isolates was performed using the Microflex LT with FlexControl version 3.4 software (Bruker Corporation, USA) for the automatic acquisition of mass spectra in the linear positive mode within a range of 2 kDa to 20 kDa. Automated analysis of the raw spectral data was performed using the MALDI BioTyper automation version 3.1 software (Bruker Corporation, USA).
The isolate was identified as S pettenkoferi (score 1.904); the top four choices were all strains of S pettenkoferi. Staphylococcus parauberis (score 1.250) was considered to be the next most likely identification.
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helped secure the identification of this organism to genus and species. The isolate was catalase positive, with a Gram-stain consistent with a Staphylococcus species, differentiating it from the next available genus identification of Streptococcus. As part of the routine processing of positive blood cultures with Gram stain suggestive of staphylococci species, polymerase chain reaction was performed for detection of methicillin resistance and to differentiate the strain from Staphylococcus aureus. Neither the nuc nor mecA genes were detected, therefore, confirming that this was a coagulasenegative methicillin-susceptible staphylococcal strain.
Susceptibility testing was performed using AST-GP67 cards on the Vitek 2 (BioMerieux, France) microbial identification system. The isolate had a minimum inhibitory concentration of 2 mg/L for oxacillin indicating that it was susceptible. Susceptibilities are listed in Table 1 .
The patient developed erythema and mild tenderness at the site of her peripheral intravenous catheter, and was diagnosed with catheter-associated bacteremia. The IV catheter was removed and her antibiotic therapy was changed to 2 g IV cloxacillin every 6 h, after having received two days of IV vancomycin. A transthoracic echocardiogram demonstrated no evidence of valvular heart disease or vegetations. Consideration was initially given to conducting a skin biopsy to better delineate the cause of the patient's rash; however, the rash resolved spontaneously. Her vertigo improved with the use of particle repositioning manoeuvres. The patient was given a prescription to complete a seven-day course of 500 mg oral cloxacillin every 6 h for six days because she had completed one day of IV cloxacillin in hospital. She was then discharged home. Repeat blood cultures taken five days after completion of antibiotic therapy were negative.
DISCUSSION
S pettenkoferi is a coagulase-negative Staphylococcus. S pettenkoferi was first described by Trülzsch et al (1) in 2002. While the authors initially reported two cases of infection with this organism (strains B3117 and A6664), subsequent investigations revealed that only one of the isolates (B3117) was S pettenkoferi (2) ; that strain was recovered from a blood culture sample in a patient with extra pulmonary tuberculosis. Since then, nine cases have been documented in the literature (Table 2 ). Trülzsch et al (2) described three more isolates of S pettenkoferi in Germany and Belgium (strain K699, isolate 229 and isolate 230) all from blood cultures, and all displaying 100% DNA-DNA homology with strain B3117 from their 2002 study. Also in 2007, the first case of S pettenkoferi osteomyelitis was described by Loïez et al (3) in France in a 63-year old diabetic man using bone biopsy cultures. Song et al (4) described the first case of S pettenkoferi in Asia in 2008 from central line blood cultures in a 76-year old man in South Korea with tuberculosis and StevensJohnson syndrome who developed bacteremia. The first South American case of S pettenkoferi was described by d'Azevedo et al (5) using blood cultures from a patient in Brazil. Other cases have also been reported including one case in Italy (6) using blood cultures and two cases in Mexico (an adult with HIV and a premature infant) using blood cultures, which were the first reported cases in North America (7). To our knowledge, this is the first case of S pettenkoferi reported in Canada. While our patient did have a history of a maculopapular rash, the rash was deemed unlikely to be related to her infection, particularly because it preceded her IV catheter insertion. We were unable to perform convalescent serology for infectious causes of rash because the patient was subsequently lost to follow-up.
It is known that coagulase-negative staphylococci are associated with infections of indwelling and implanted devices (8) . This is possibly consistent with the present patient's presentation, although a peripheral IV site was believed to be involved in her case. With regard to antibiotic choice, different agents have been used (see Table 2 ). To the best of our knowledge, our patient was the first to be treated successfully with cloxacillin, albeit having previously received a short course of vancomycin (Table 1) .
We suspect that S pettenkoferi is significantly more commonly encountered than the above reports would suggest. Laboratory identification can be challenging because biochemical tests may result in misidentification of S pettenkoferi as Staphylococcus hominis, Staphylococcus auricularis, Staphylococcus capitis and Kocuria varians ( Table 2 ). In several situations, the correct identity of the bacterium was not made until molecular tests, such as 16S ribosomal RNA (rRNA) gene sequencing were performed. Notwithstanding, while genetic sequencing of 16S rRNA has been the most commonly used method to confirm the diagnosis of S pettenkoferi, strain A6664, one of the two originally described S pettenkoferi isolates, has a slightly different rpoB gene sequence and does not have 100% DNA-DNA homology with the other strains described in 2007 by Trülzsch et al (2) compared to strain B31117. This suggests that it is a different species altogether and, therefore, 16S rRNA gene sequencing may not be sufficiently robust to definitively diagnose the presence of S pettenkoferi.
A limitation of our study is the lack of sequencing data because the isolate is no longer available. Nevertheless, we believe that in the present case the species diagnosis is confirmed. Our laboratory uses MALDI-ToF mass spectrometry. MALDI-ToF has been used to correctly identify other coagulase-negative staphylococci that have been under-reported in the past, such as Staphylococcus lugdunensis (9) . The use of MALDI-ToF may result in increased reports of S pettenkoferi infection. In studies performed at our institution, the Bruker MALDIToF correctly identified 485 of 485 coagulase-negative staphylococci to the species level. Included in these were 117 isolates of S capitis and S hominis species that were all identified correctly by the MALDI-ToF with none being identified as S pettenkoferi (10, 11) .
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